Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELEX: Lapatinib and Trastuzumab for HER2+ Breast Cancer
NCT00999804Phase 2Active, not recruiting
- Sponsor
- Baylor Breast Care Center
- Start
- Oct 2011
- Primary completion
- Nov 2014
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lapatinib and trastuzumab in breast cancer, sponsored by Baylor Breast Care Center. Started Oct 2011; status: active, not recruiting.
02
Drugs
lapatinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00999804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00999804.